Business & Regulation

What do companies need to consider when developing next-gen medicines for rare diseases?

The COVID-19 pandemic exposed weaknesses in pharma supply chains. It’s time to address these.

Medicare publishes policy for amyloid mAbs and Alzheimer’s disease. It’s not good news for Aduhelm.

Get excited, because the results are in! Find out who won the 2022 Innovation Awards

African vaccine production needs a boost. Here’s how Aspen is working to make that happen.

We sat down to talk shop with Novo Nordisk Executive Vice President Ludovic Helfgott

One decade behind the EU, biosimilars are arriving in the US. What can we expect? Jeff Baldetti from Cardinal Health has a few ideas.

How an initiative from EFPIA and a new public database on chemical substances could reduce animal experiments.

Medicines Patent Pool has joined forces with over 30 generic manufacturers to help ensure access to anti-COVID-19 medicines for all.

What are the key decisions that need to be made for cell therapy supply chains?